Yamanouchi Pharmaceutical Co., Ltd. To License Gelpart Coronary Embolism Material To Nippon Kayaku Co., Ltd.
10/19/2005 5:12:39 PM
Tokyo (JCNN) - Yamanouchi Pharmaceutical has announced that it has concluded a licensing agreement with Nippon Kayaku for its proprietary product Gelpart. Under the terms of the agreement, Nippon Kayaku will receive the exclusive rights to Gelpart.
comments powered by